Alien Metals

Alien’s strategic joint venture partner and investee company, Greentech Metals Limited (‘GreenTech’, ‘the Company’, ASX: GRE), has announced receipt of firm commitments for an oversubscribed AUD$7.5m (gross) equity placement (the ‘Placing’) priced at AUD$0.075/share (which is the previous day’s closing price and a 10.3% discount to the 10-day VWAP). 

Alien Metals: Research

Orosur Mining Inc.

Orosur continues to deliver on its promises. Ongoing drilling at Pepas West has produced further positive Au results, recording thick intersections of shallow mineralisation. Significantly, one particular hole (PEP090) that is stepped out 30m to the north-west of previous holes, demonstrated mineralisation over 100m in strike.

Orosur Mining: Research

Orosur has released assay results for five more holes from its Pepas Prospect (‘Pepas or ‘the Prospect’) Mineral Resource Estimate (‘MRE’) infill program. High grade intersections, including PEP060: 63.55m @ 8.23g/t Au and PEP064: 49.96m @ 4.29g/t Au, remain consistent with management expectations and progress work required for development of a three-dimensional geological model of the in-situ mineralisation

Zephyr has released much-anticipated highlights from an updated Competent Person’s Report (‘CPR’) covering its assets in the Paradox Basin, Utah (the ‘Paradox Project’). 

Zephyr Energy: Research

N4 Pharma

N4 Pharma (‘N4P’) has released further details and findings from its collaboration (‘the Collaboration’) with world-renowned nonprofit R&D institute SRI International (‘SRI’). The combination of SRI’s MGS targeting molecules with Nuvec®, has demonstrated ability to successfully deliver therapeutic RNA (‘siRNA’) payloads to target cell types, in this case specifically non-small cell lung cancer cells. 

N4 Pharma: Turner Pope

Responding to continuing exceptional drilling results from its Pepas prospect (‘the Prospect’) and the wider opportunity presented through its Colombian Anzá gold exploration project (the ‘Project’), Orosur has announced its second-best efforts private placement (the ‘Marketed Offering’) of 2025. Following March’s CAD$6m* brokered raise, the Group is now seeking gross proceeds of up to CAD$15.0m (c.£8.0m*) through an issue of new common shares priced at CAD$0.34 (or c.18.1p*)

Orosur Mining: Turner Pope

Metir has announced a new contract with Aptamer Group plc for the development of Optimer® binders for rapid Cryptosporidium detection using its next-generation, pathogen monitoring platform. For Metir, this collaboration (the ‘Collaboration’) represents an important step forward in its strategy to deliver a market-leading, real-time water monitoring solution. For Aptamer, it commences a development agreement first established with Metir on 14 June 2024 for creation of new bin

Metir: Turner Pope

Orosur has released assay results for six more holes from its Pepas Prospect (‘Pepas or ‘the Prospect’) Mineral Resource Estimate (‘MRE’) infill program. Significantly, while these continue to firm up understanding of the orebody and provide better definition of the nature of the thick, high-grade mineralisation, newly drilled PEP055 also unexpectedly intersected an extremely high-grade vein (comprising coarse gold of 15.25g/t over 47.25m at a downhole depth of only 30m). 

Aptamer Group plc

Aptamer has provided an update on its enzyme modulation projects and a development project with a top five pharmaceutical company. These together represent further important advancements in the Group’s licensing and development. With multiple non-exclusive licensing opportunities for its first enzyme-modulating Optimer® already in place, Aptamer has now received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific applicatio

Aptamer Group: Turner Pope

Aptamer’s ongoing strategic asset development partnership with fast moving consumer goods (‘FMCG’) giant, Unilever plc (LSE: ULVR), has taken yet another important step forward, with a new paid work package that supports further development of deodorant Optimers. This latest extension for expanded stability testing is a critical advancement toward on-person trials and validates the superior performance the Group’s formulations have achieved to date. Partnering with Unilever, 

Avacta Group

Avacta has undertaken a conditional placing (‘the Placing’) of 10.83m new shares raising £3.25m (gross) at 30p each (being a discount of c.7.7% the closing price on 16 July 2025) from long term, high net worth investors. Admission of the new shares is expected to take place on or around 24 July 2025.

Avacta: Turner Pope

Alien has released two significant news announcements in as many weeks. On 3rd July it delivered on two of the near-term catalysts it identified back in May 2025, when undertaking a £1m (gross) equity placing (‘the Placing’) in anticipation of accelerating development of its Hancock Iron Ore Project (‘the Project’). 

Alien Metals: Turner Pope

Following a number of positive updates, Aptamer has undertaken a placing (‘the Placing’ or ‘the Fundraise’) to raise up to £2.0 million (gross) through the issue of up to 666.67m new ordinary shares at 0.3p each to new and existing shareholders. Priced at a discount of c.21.1% to the closing on 3 July 2025, the Fundraise comprises a firm placing of c.400.42m new shares (the ‘First Admission’) for which dealings are expected to commence on or around 9 July 2025 and; a conditio

TheraCryf has released Final Results for its 12 months to 31 March 2025. These confirm the enlarged Group continues to deliver on operational/financial expectations as it enters a particularly active phase of works that could see considerable value being added to the business as it brings forward new treatment options in areas of real unmet medical needs.

TheraCryf: Turner Pope

Orosur has released assay results from five more holes at its Pepas and North Pepas prospects. These provide further strong intersections, add substantially to the geological understanding of the underlying body and open potential for additional extensions. 

Alien has announced a placing (the ‘Placing’) of new common shares (the ‘Fundraising Shares’) to raise £1.0m (gross) from certain institutional and other investors. The issue price of 0.08p, represents a discount of 15.8% to the mid-market closing price of 0.0925p on 21 May 2025.

Aptamer has today issued two separate news releases. One of them covers new data that was released at the 2025 American Society for Gene and Cell Therapy (‘ASGCT’) Annual Meeting (13 - 17 May 2025) confirming Aptamer’s Optimer® delivery vehicle, which was originally developed for liver fibrosis, has also been found to be capable of targeting other similarly diseased organs, including the kidney, skin and heart.

Aptamer: Turner Pope

N4 Pharma (‘N4P’ ) has released positive results from the first in vivo study of its dual-loaded Nuvec® proof-of-concept (‘POC’) programme, N4 101, an orally delivered treatment for Inflammatory Bowel Disease (‘IBD’). Data indicates a sustained anti-inflammatory effect in a validated model through targeted treatment of nucleic acid therapeutics.

Zephyr has reported quite exceptional initial results from its flagship State 36-2 LNW-CC-R well (the ‘Well’) in the under-explored Paradox Basin, Utah. The single well produced a peak rate of 2,848 barrels of oil equivalent per day (‘boepd’), in the form of 11.9 million standard cubic feet per day (‘mmscfd’) and 856 barrels of oil per day (‘bopd).

Zephyr Energy: Turner Pope

N4 Pharma (“N4P”) has raised £1.75m (gross) new funding through an equity placing and subscription (‘the Fundraising Shares’) priced at 0.40p/share (representing a 5.9% discount to Monday’s close). Each placing and subscription share will have one warrant attached, exercisable at 0.8p for a period of three years from the second admission date.

Assay results from three further holes in the central zone of the Pepas Prospect (‘Pepas’ or ‘the Prospect’) continue to build-out an exceptionally exciting geological picture. Adding to the list of outstanding gold intersections delivered in the six weeks since Orosur regained control of the Anzá Project (‘the Project’) in Colombia, holes PEP016, PEP017 were drilled with the objective of increasing understanding of the litho-structural framework of the deposit, while PEP018 

Orosur has been undertaking early, close-spaced drilling in order to identify and attempt to better understand its Pepas prospect (‘the Prospect’), which is located in the northern extent of the Group’s flagship Anzá Project (pre acquisition) (‘the Project’) in Colombia. 

Orosur has raised £1.25m (gross) new funding through an equity placing (the ‘Placing’) priced at 6.6p/share (representing a c.25% discount to Toronto and London’s mid-market close on 18 December 2024. 

Orosur: Turner Pope

A newly released TR-1, being the standard form for notification of major holdings, details 1832 Asset Management L.P. (‘1832AMLP’) as having recently become a holder of 5.72% of Orosur’s ordinary share capital. The position is held through the Bank of Nova Scotia’s (TSX: BNS) Dynamic Precious Metals Fund (itself a mutual managed by wholly-owned 1832AMLP). 

Aptamer has published news detailing strong technical progress across a number of its ongoing strategic projects with global consumer goods and pharmaceutical partners. Each continue to produce positive results, providing increased validation and progression towards commercial products with potential to deliver value inflection points for the Group across diverse applications.

Orosur has published assay results from the first hole of its new drilling programme at the Pepas prospect. Coming hard on the heels of two releases earlier this month, confirming that the Group had both assumed 100% ownership and operatorship of its flagship Anzá Gold Project in Colombia (the ‘Anzá Project’) with no upfront payments and that the first in a series of six or seven exploratory holes had already been completed, today’s news that PEP012 delivered an exceptional 6

Two recent announcements have reinforced expectation that Aptamer will be able to deliver on both its revenue and licensing goals for FY2025/26. These were set on 24 July 2024, following the Group’s successful £2.83m (gross) equity fund raise. 

Zephyr has announced its decision to drill a lateral extension on the State 36-2R well (‘the Well’), while confirming a non-binding letter of intent (the ‘LOI’) has been signed with a US-based industry investor (‘the Investor’) to fund 100% of the estimated cost. 

Unaudited interim results for the six months ended 30 June 2024 have been released. In terms of financials these provided little in the way of surprises, while the Board continued to stress the exceptional progress being made with its drug development candidate AVA6000, along with a high level of confidence in the capabilities of its pre|CISION™ platform.

Avacta Group: Turner Pope

Orosur has raised £0.835m (gross) new funding through an equity placing (the ‘Placing’) priced at 2.78p/share (representing a c.15% discount to the mid-market close on 27 September 2024); each two Placing shares has one unlisted warrant attached, which is exercisable for 2 years from Admission at c.US$0.0494 (approximately 3.697p**) into one new common share.

Zephyr has released its half-year results up to the end of June 2024. The report highlights significant progress at its flagship asset in the Paradox Basin, alongside consecutive quarterly growth in non-operated production from the Williston project. 

Aptamer has announced an extension to its partnership with Unilever plc (LSE: ULVR). This new phase aims to commence in-vivo efficacy testing ofOptimer® binders as active ingredients in deodorants before the end of 2024.This represents a significant endorsement of the Group’s technology with opportunity to create a long-term interdependent relationship with the consumer goods giant. 

While providing an update on the Group’s Salt Wash helium project (the ‘Farm-in’), Zephyr has also confirmed that the State 36-2R well’s second phase production test and evaluation is now nearing completion.

Aptamer has undertaken a firm and conditional equity placing and subscription (‘the Placing’), raising £2.83m (gross) funding through placement of 1,415m new ordinary shares priced at 0.2p each. 

Drilling operations on the State 36-2R LNW-CC well (‘the well’) at the Group's flagship project in the Paradox Basin, Utah, were completed safely on 4 June 2024, having successfully achieved to a total depth of 10,290 feet (measured depth).

Orosur has provided an update on exploration activities at its El Pantano gold and silver project (‘Project’ or ‘El Pantano’) in Argentina. Results clearly underline the region’s potential, with low-cost generation of a highly prospective array of gold targets amid a presently buoyant market for the precious metal.

Orusur Mining: Turner Pope

Having reached a pivotal point in its evolution, Dr Christina Coughlin was appointed as Avacta’s new Chief Executive Officer (effective 1 May 2024), with a view to steering the Group through its coming chapter of growth and transformation into a therapeutics-focused business.

N4 Pharma and Silicon Valley-based SRI International (‘SRI’) have entered a research collaboration agreement (‘the Agreement’) designed to progress development of preclinical products capable of overcoming barriers that prevent intracellular delivery of large molecule biotherapeutics. 

Nanoco yesterday released its half year results to 31 January 2024 (‘the Period’). Very much in line with expectations, these following confirmation of the Group’s Final Litigation proceeds earlier this month along with a proposal to shortly return up to £33m to Shareholders (the ‘Return of Value’, abbreviated remaining timetable below).

Nanoco: Turner Pope

Aptamer has published its unaudited first half results to 31 December 2023 (the ‘Period’). Confirming core detail provided in its Half Year Trading Update released on 5 February 2024, the financials are very much in line with expectations, while the Board continues to report strong technical delivery leading to growing commercial traction.

Aptamer Group Plc: Turner Pope

Zephyr has provided an update on its Salt Wash Helium project (‘the Project’). While stating that it is not seeking for helium to become a primary focus of the Group, the Board do consider it offers significant and currently unrecognised potential value for Shareholders, particularly in consideration of the growing supply-demand imbalance that has recently been seen to drive prices up to US$1,000 per million standard cubic feet 

Orosur has taken an important first step toward resuming 100% ownership of the Anzá Project (‘Anzá’ or ‘the Project’), targeting completion of a transaction (‘the Transaction’) by the end of April 2024. 

Following receipt of its Final Litigation proceeds, Nanoco now proposes to return up to £33.0m to Shareholders. 

Avacta has undertaken an equity Placing (the ‘Placing’), raising a total of c.£25.7m new funding priced at 50p/share (the ’Offer Price’). 

Microsaic, on Friday 16 February, provided an update detailing progress following its recent acquisition of certain assets and intellectual property of the Modern Water business (the ‘Acquisition’), whose integration is going ahead as planned.

Microsaic Systems Plc: Turner Pope

Orosur has announced a modest fundraise of £0.50m (gross) through an equity placing priced at 2.95p/share, together with a grant of one unlisted warrant (‘Warrant’) at 50% premium for every Placing share subscribed (together the‘Placing’)

N4P has released a further, highly encouraging update from its ongoing in vitro siRNA research work. This demonstrates a strong beneficial effect on cellular inhibition from combined loading of EGFR (epidermal growth factor receptor) and PLK1 (Polo Like Kinase 1) onto the same Nuvec® nanoparticle, compared to single-dose siRNA when tested in PC9 lung cancer cells.

N4 Pharma plc: Turner Pope

Aptamer has provided a first half trading update to 31 December 2023 in which it warns that the current year revenue target of £3m it set with release of its full year results to 30 June 2023 is now expected to be missed. Clear progress has nevertheless been registered since the Group confirmed its £3.6m (gross) fund raise and boardroom changes on 31 July 2023. 

Microsaic confirms its acquisition of certain assets and intellectual property of the Modern Water business (the ‘Acquisition’) previously operated by the now delisted DeepVerge plc, the successful undertaking of a conditional equity fundraise (the ‘Revised Fundraise’) of c.£2.1m (gross) at 1.25p/share (representing a c.70% discount to the equivalent pre-consolidation closing mid-market price on 30 June 2023)